CeleCor Submits FDA NDA for Zalunfiban After Phase 3 Success
DEL MAR, Calif., June 24, 2026 CeleCor Therapeutics announced the completion of its New Drug Application (NDA) submission to...
cardiovascular disease
Advertisement
Diazyme Laboratories Secures FDA Clearance for Lp(a) Assay
POWAY, Calif., June 17, 2026 Diazyme Laboratories, Inc. has received U.S. FDA 510(k) clearance for its Lipoprotein(a) [Lp(a)] Molarity...
VahatiCor Enrolls First U.S. Patient in A-FLUX SERRA-I Trial
SANTA CLARA, Calif., June 17, 2026 VahatiCor, Inc., a medical device company focused on developing innovative therapies for coronary...
AccurKardia’s AK-AVS Joins FDA TAP Program for AI Heart Screening
NEW YORK, June 16, 2026 AccurKardia announced that its AK-AVS™ aortic valve stenosis screening software has been accepted into...
AbbVie Strengthens Blood Cancer Leadership with New EHA 2026 Clinical Findings
NORTH CHICAGO, Illinois, USA – June 8, 2026 AbbVie has announced the presentation of new clinical and translational research...
Advertisements
Vasa Therapeutics Presents New VS-041 Data for HFpEF at ECM2026
ENCINITAS, California, USA & WROCLAW, Poland – June 8, 2026 Vasa Therapeutics, a clinical-stage biotechnology company focused on therapies...
BioCardia Gains FDA Support for Heart Failure Therapy
SUNNYVALE, Calif., June 5, 2026 BioCardia, Inc. announced that it has received official meeting minutes from the U.S. Food...
Tenaya Reports Positive TN-201 Gene Therapy Data in MYBPC3-Associated HCM
SOUTH SAN FRANCISCO, Calif., June 3, 2026 Tenaya Therapeutics announced new interim data from its ongoing MyPEAK™-1 Phase 1b/2...
Chiesi Wins EU Approval for Pediatric LOJUXTA Use
PARMA, Italy, June 5, 2026 Chiesi Global Rare Diseases has announced a major regulatory milestone following the European Commission’s...
Tenaya Therapeutics Prepares New TN-201 Gene Therapy Data for Genetic Heart Disease
SOUTH SAN FRANCISCO, Calif., June 2, 2026 Tenaya Therapeutics announced that it will present new interim clinical data from...
Advertisement
